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ABSTRACT 
Asymmetric dimethylarginine (ADMA) is a naturally occurring methylated amino acid which is 
released into the circulation during protein metabolism. Elevated ADMA levels reduce the formation of 
nitric oxide (NO) by inhibiting nitric oxide synthase and are associated with endothelial dysfunction. The 
female sex hormone, estrogen, is known to have an effect on ADMA concentration by regulating the 
expression of ADMA degrading enzyme dimethylarginine dimethylaminohydrolase (DDAH). Earlier it 
has been observed that the ADMA concentration is elevated in women with complicated pregnancies, 
such as pre-eclampsia. 
In the present series of studies, the effects of hormonal cyclic changes on the levels of ADMA and its 
related compounds were investigated in healthy non-pregnant women with and without hormonal 
contraceptive use. Another aim was to examine if there was an association between ADMA levels and 
flow-mediated dilatation and factors that are known to be involved during normal pregnancy, such as 
hypercholesterolemia and changes in the immune system. 
In order to measure the concentrations of ADMA, symmetric dimethylarginine (SDMA), L-
homoarginine and L-arginine in human serum and plasma, the HPLC method developed by Teerlink et al. 
(2002) was optimized and it proved to have good recovery, excellent linearity, low detection limits and 
good separation efficiency of the analytes. ADMA and its related compound concentrations were 
measured from two study populations; The Cardiovascular Risk in Young Finns Study and The 
Complicated Pregnancy Study. Brachial artery flow-mediated dilatation (FMD) was measured by 
ultrasound. 
It was found that the ADMA concentration was dependent on hormonal status of women without oral 
contraceptive (OC) use. The use of oral contraceptives decreased ADMA and SDMA concentrations as 
compared with non-OC users but there was no variation in the ADMA concentration during menstrual 
cycle phases in women with OC-use. Furthermore, it was found that ADMA, SDMA and L-arginine 
concentrations declined and L-homoarginine concentrations were elevated in normal pregnancy in 
comparison with the levels in non-pregnant females. During normal pregnancy, serum levels of ADMA 
and SDMA were not associated with hypercholesterolemia or circulating cytokines, IL-6 and TNF-α, or 
C-reactive protein. FMD was enhanced in normal pregnancy but it was not associated with ADMA levels. 
In summary, the present studies provide new information about ADMA and related compounds 
regarding pregnancy related phenomenon: endothelial function, immune system upregulation and 
increased lipid concentration during normal pregnancy. In this thesis, it was found that the ADMA 
concentration varied during menstrual cycle. Thus if women of fertile age are used in studies, the 
menstrual cycle phase and not only their possible use of hormonal contraception should be taken into 
account. Furthermore, also the type of contraception is important. This applies also to CRP measurements 
where the use of OC has been shown to increase the circulating CRP concentration. On the contrary, 
endothelial function measured as FMD seemed to be unaffected by the menstrual cycle phase. These 
results may be useful when ADMA concentrations from normal pregnancy are compared with the results 
from complicated pregnancies. 
National Library of Medicine Classification: WQ 244, QU 60 
Medical Subject Headings: Humans; Female; Pregnancy; Arginine/blood; C-Reactive Protein; Cytokines;  
Homoarginine/blood; Interleukin-6/blood; Endothelium, Vascular; Menstrual Cycle; Nitric Oxide/blood; 
Tumor Necrosis Factor-alpha; Vasodilation 
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1 INTRODUCTION 
There is abundant evidence that endothelial cells play a crucial role in the maintenance 
of vascular tone by producing several vasoactive agents. One of the major endothelium-
derived vasoactive mediators is nitric oxide (NO). Asymmetric dimethylarginine 
(ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) since it can 
compete with the binding of the natural substrate L-arginine (Vallance et al. 1992). 
ADMA is a naturally occurring methylated amino acid and a post-translationally 
modified form of arginine that is generated in all cells during the process of protein 
turnover. It is eliminated from the body by a combination of renal excretion and 
metabolism by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This 
enzyme plays a critical role in the regulation of the cellular and tissue levels of ADMA 
(Ogawa et al. 1987). Thus, the inhibition of DDAH leads to accumulation of ADMA 
within cells (MacAllister et al. 1996). Several studies have demonstrated that ADMA is 
a useful marker of endothelial dysfunction and elevated concentration of ADMA has 
been reported in a number of diseases such as hypercholesterolemia (Böger et al. 1998), 
hypertension (Goonasekera et al. 1997), diabetes (Päivä et al. 2003), renal failure 
(Vallance et al. 1992), pre-eclampsia (Savvidou et al. 2003) and chronic heart failure 
(Usui et al. 1998). The elevated ADMA concentration was also associated with an 
increased risk of adverse cardiovascular events and atherosclerosis (Miyazaki et al. 
1999; Valkonen et al. 2001; Mittermeyer et al. 2006; Krzyzanowska et al. 2007b). 
There are a variety of methods for determining plasma concentration of ADMA and 
these have been used to examine the association between various disease states and 
endothelial function (Cooke 2000; Perticone et al. 2005). The most widely used 
methods for the determination of ADMA are based on chromatographic analysis by 
high-performance liquid chromatography (HPLC) with fluorescence detection 
(Pettersson et al. 1997; Teerlink et al. 2002; Marra et al. 2003; Heresztyn et al. 2004; 
Zhang and Kaye 2004). These techniques permit the simultaneous determination of 
ADMA, its isomer symmetric dimethylarginine (SDMA) and L-arginine. Recently, 
methods based on mass spectrometry (MS) have also been developed (reviewed in 
Martens-Lobenhoffer and Bode-Böger 2007). Furthermore, a commercially available 
16
enzyme-linked immunosorbent assay (ELISA) for ADMA (Schulze et al. 2004) with 
high sample throughput has been developed but it is not able to assay L-arginine or 
SDMA simultaneously with ADMA. 
Normal pregnancy is associated with enhanced vasodilatation, since there are many 
vasodilatory systems, such as the increased NO production (reviewed in Valdes et al. 
2009). In addition, the circulating plasma level of ADMA decreases during normal 
pregnancy (Holden et al. 1998; Pettersson et al. 1998; Ellis et al. 2001; Savvidou et al. 
2003) but is often elevated in endothelial dysfunction and pregnancy complications, 
such as preeclampsia (Fickling et al. 1993; Holden et al. 1998; Savvidou et al. 2003). In 
the present series of studies, the aim was to examine if there is an association of ADMA 
or related compounds with factors that are involved in normal pregnancy and may be 
detrimental to health under non-pregnant circumstances, such as hypercholesterolemia 
and changes in the immune system. First, the HPLC method developed by Teerlink et 
al. (2002) was optimized and evaluated against a new commercially available ELISA 
assay. Secondly, the effect of menstrual cycle phase and oral contraceptive (OC) use on 
dimethylarginine and L-arginine concentrations was evaluated. The concentrations of 
ADMA, SDMA, L-homoarginine and L-arginine were measured by HPLC in non-
pregnant and pregnant women. In addition, the relationship between ADMA and flow-
mediated dilatation (FMD), hypercholesterolemia, and inflammation markers was 
examined in non-pregnant and pregnant state. 
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2 REVIEW OF THE LITERATURE 
2.1 L-arginine-nitric oxide pathway 
The L-arginine-nitric oxide pathway is involved in the regulation of a wide variety of 
physiological functions including endothelium-dependent vasodilation, platelet 
aggregation, neurotransmission, immune defence and apoptosis (Moncada and Higgs 
1993). Nitric oxide is synthesized from the amino acid L-arginine by the action of nitric 
oxide synthases (Figure 1), a family of enzymes with endothelial, neuronal, and 
inducible isoforms (Palmer et al. 1988; Furchgott 1996). Synthesis of NO can be 
blocked by ADMA, which is able to inhibit all isoforms of NOS (Vallance et al. 1992; 
MacAllister et al. 1994). Additionally, NG-monomethyl-L-arginine (L-NMMA) 
produces near-identical effects on ADMA, but its concentration in plasma is about ten-
fold lower (Furchgott 1996; Matsuoka et al. 1997; Cardounel and Zweier 2002). SDMA 
cannot directly inhibit NOS, but it is able to indirectly reduce intracellular L-arginine 
availability and limit NO synthesis by competing with L-arginine, ADMA and L-
NMMA for cellular transport by one of the cationic amino-acid transporters (y+ 
transporter). 
Figure 1. Nitric oxide production by nitric oxide synthase (NOS) in L-arginine-nitric 
oxide pathway. 
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2.2 Metabolism and clearance of dimethylarginines 
The plasma concentration of ADMA is a complex result of many parallel processes 
occurring in a variety of organs (Figure 2). ADMA is formed by proteolysis of proteins 
with arginine residues which are methylated by protein arginine methyltransferases 
(PRMTs). Two other endogenous methylarginines are also synthesized by PRMT: L-
NMMA and SDMA, an isomer of ADMA. The structures of ADMA and related 
compounds are depicted in Figure 3. 
Figure 2. Biochemical pathways for generation of ADMA and its degradation by enzyme 
dimethylarginine dimethylaminohydrolase (DDAH) in cells. 
ADMA, asymmetric dimethylarginine; L-Arg, L-arginine; NO, nitric oxide; NOS, nitric oxide 
synthase; PRMT, protein arginine methyltransferase; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine. 
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Figure 3. L-arginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine 
(SDMA), NG-monomethyl-L-arginine (L-NMMA) and L-homoarginine structures.
Although the overall physiological roles of PRMTs are not clear, one of their 
functions appears to be regulation of mRNA processing and maturation by modulating 
the activity of RNA-binding proteins. However, it has been shown that PRMT-1 
catalyzes the formation of ADMA and L-NMMA, whereas PRMT-2 leads to the 
formation of SDMA (Gary and Clarke 1998). A recent proteomic analysis has identified 
more than 200 proteins that are putatively arginine-methylated (Boisvert et al. 2003). 
Many of these proteins, such as histones, RNA binding proteins, cytokine receptors, and 
MRE11, play a regulatory role in important cellular processes such as transcription, 
RNA processing, signal transduction, and DNA repair (reviewed in Bedford and 
Richard 2005). Even though the methylation of arginine residues on proteins seems to 
be ubiquitous, the degree of arginine methylation is organ specific and elevated 
dimethylarginine residues have been shown to be present in brain, liver, lung, spleen, 
kidney and small intestine (Nakajima et al. 1971). 
Protein degradation represents the major source of intracellular and plasma arginine 
and methylarginines. Proteolysis usually results in complete degradation of proteins to 
free amino acids, which in turn can be used for de novo protein synthesis. Post-
translationally modified amino acids cannot be used for protein synthesis and must be 
excreted or metabolized. Recently, one demethylating enzyme has been found that can 
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deaminate monomethylated arginine residues but it does not seem to be able to 
hydrolyse ADMA (Cuthbert et al. 2004). Another study has found that proteins with 
methylated arginine residues are degraded rapidly (Teerlink 2005a). It was reported that 
a homogenate of rat kidney rapidly released free ADMA in an in vitro incubation. 
Asymmetric dimethylarginine is continuously released into the extracellular space 
after its release from proteins during physiological protein turnover. In healthy humans, 
its accumulation in the body is prevented by both renal excretion, and metabolic 
degradation. Most ADMA (and L-NMMA) is hydrolyzed by an intracellular enzyme 
called dimethylarginine dimethylaminohydrolase into citrulline and dimethylamine and 
only a small proportion of ADMA is excreted into urine through the kidneys (Ogawa et 
al. 1989). On the contrary, DDAH does not exhibit activity towards SDMA. The 
Michaelis-Menten constant of DDAH for ADMA is 0.18 mM which is much higher 
than the intracellular concentrations of ADMA (Ogawa et al. 1989). This ensures that 
ADMA is efficiently degraded as the enzyme is functioning in the linear part of the 
substrate-velocity curve. It is not known what percentage of the endogenously formed 
ADMA is directly metabolized in the cells where it has been formed, and how much is 
released from the cells to other tissues to be metabolized or excreted. There are two 
DDAH isoforms (DDAH-1 and DDAH-2) with different tissue distributions (Leiper et 
al. 1999). DDAH-1 is mainly expressed in the kidney and liver, which are also the 
major sites of ADMA metabolism (Nijveldt et al. 2003a and 2003b). DDAH-2 is 
particularly abundant in the vascular endothelium, heart, placenta and kidney (Tran et 
al. 2000). Interestingly, it has been recently demonstrated that the lungs may be a major 
source of ADMA (Bulau et al. 2007). In studies conducted in rats, a very high uptake of 
ADMA by the liver was found (Nijveldt et al. 2003a), which can be considered as 
evidence for the important role of the liver in regulating the systemic ADMA 
concentration. It has also been demonstrated that DDAH is co-localized with NOS in 
several anatomical sites (Tojo et al. 1997). Thus, the substrate specificity of DDAH and 
its co-localization with NOS have provided the basis for the concept that regulation of 
intracellular ADMA levels may occur via DDAH, which in turn might regulate NOS 
activity. 
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Changes in renal excretory function or changes in DDAH activity may lead to 
elevated ADMA levels in several cardiovascular and metabolic diseases. Although 
increased NO synthesis due to upregulation of DDAH expression or activity is usually 
desired in cardiovascular diseases, it may have undesirable effects in tumors. In these 
situations, overexpression of both DDAH isoforms has been demonstrated to enhance 
tumor growth and promote tumor angiogenesis (Kostourou et al. 2002). These 
observations suggest that neither very high nor very low NO and ADMA levels are 
desirable, and NO and ADMA concentrations must be kept between certain limits in 
plasma and normal tissues. 
2.3 Analysis methods of ADMA 
The measurement of ADMA concentrations in plasma has been a focus of interest since 
its association with NO metabolism was discovered in 1992 (Vallance et al. 1992). To 
date, a broad range of methods for dimethylarginine assay has been published 
(Vishwanathan et al. 2000; Wahbi et al. 2001; Teerlink et al. 2002; Marra et al. 2003; 
Tsikas et al. 2003; Schulze et al. 2004; Trapp et al. 2004; Xu et al. 2004; Horowitz and 
Heresztyn 2006). However, there are large discrepancies in the dimethylarginine values 
reported with these methods which may be due to different sample purification steps 
and the different methods used for the analysis (Table 1). 
2.3.1 Chromatographic methods 
Most methods that are intended to measure ADMA are based on HPLC with sensitive 
fluorescent detection (Pettersson et al. 1997; Teerlink et al. 2002; Marra et al. 2003; 
Heresztyn et al. 2004; Zhang and Kaye 2004). The methods allow chromatographic 
separation of these two structurally very similar, but functionally completely different 
isomers, ADMA and SDMA. The HPLC methods are hampered by the laborious 
sample preparation necessary to detect the small amounts of analyte present in human 
plasma and serum, and protein precipitation or solid phase extraction is normally used 
(Bode-Böger et al. 1996; Anderstam et al. 1997). Protein precipitation can be 
performed with 5-sulfosalicylic acid (Anderstam et al. 1997; Chen et al. 1997) or 
ethanol (Zhang and Kaye 2004). The samples need to be diluted with water or buffer to 
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avoid clogging of proteins in the extraction column. These columns can be either silica 
based or equipped with a polymeric stationary phase. Stationary phases are usually 
modified with weak carboxylic acid or strong cation exchange resins (Bode-Böger et al. 
1996; Pettersson et al. 1997; Teerlink et al. 2002). Recoveries for L-arginine are 
crucial, and protocols need to be optimized in this respect (Teerlink et al. 2002; 
Heresztyn et al. 2004). Furthermore, only volatile compounds can be used for analyte 
elution from the extraction column, because the solvent is removed by evaporation. 
Sample cleanup by solid phase extraction is labour intensive, but the procedure can be 
fully automated (de Jong and Teerlink 2006). 
Table 1. Summary of the mean basal plasma or serum ADMA, SDMA and L-arginine concentrations in 
normal control subjects obtained with different methods. 
Method ADMA SDMA L-Arg n Reference 
 (μM) (μM) (μM) 
HPLC (OPA) 1.25 ± 0.11 0.71 ± 0.09 83 ± 5 47 Böger 1997 
HPLC (OPA) 0.58 ± 0.02 0.56 ± 0.02  10 Pettersson 1997 
HPLC (OPA) 0.51 ± 0.01   116 Miyazaki 1999 
HPLC (OPA) 1.3 ± 0.2 0.7 ± 0.2 60 ± 6 24 Chan 2000 
HPLC (OPA) 0.51 ± 0.16 0.39 ± 0.12 140 ± 29 150 Valkonen 2001 
HPLC (isotope) 0.61 ± 0.13 0.41 ± 0.12 118 ± 18 9 Wahbi 2001 
HPLC (OPA) 1.4 ± 0.7 0.64 ± 0.41 59 ± 9 16 Kielstein 2002 
HPLC (OPA) 0.47 ± 0.03 0.50 ± 0.03  17 Mittermayer 2002 
HPLC (OPA) 0.42 ± 0.06 0.47 ± 0.08 94 ± 26 53 Teerlink 2002 
HPLC (OPA) 0.43 ± 0.12 0.33 ± 0.08 118 ± 31 47 Päivä 2002 
HPLC (NDA) 0.38 ± 1.3 1.32 ± 2.7  50 Marra 2003 
HPLC (OPA) 0.93 0.27 85 20 Eid 2003 
HPLC 0.66 ± 0.04 0.49 ± 0.03 76 ± 4 26 Fleck 2003 
HPLC 0.41 ± 0.06  81 ± 23 NM Maeda 2003 
HPLC (OPA) 0.30 ± 0.05 0.34 ± 0.06 61 ± 19 7 Pi 2000
HPLC (OPA) 0.50 ± 0.06   726 Teerlink 2005b 
HPLC (AccQ) 0.50 ± 0.09   157 Horowitz 2006 
CE 0.34 ± 0.02  85 ± 6 5 Caussé 2000 
CE 0.42 ± 0.02  27 ± 4 NM Trapp 2004 
LC-MS 0.12 ± 0.05 0.16 ± 0.07 63 ± 24 20 Vishwanathan 2000 
LC-MS 0.48 ± 0.07 0.41 ± 0.05 72 ± 17 40 Huang 2004
LC-MS/MS 1.41 ± 0.05   25 Selley 2003 
LC-MS/MS 0.35 ± 0.01 0.51 ± 0.01  14 Xu 2004 
LC-MS/MS 0.46 0.68  42 Kirchherr 2005 
LC-MS/MS 0.37 ± 0.06 0.45 ± 0.06 60 ± 18 14 Martens-L. 2006 
GC-MS/MS 0.39 ± 0.06   12 Tsikas 2003 
GC-MS 0.60 ± 0.08   10 Albsmeier 2004 
ELISA 0.72 ± 0.16   10 Schulze 2004 
ELISA 0.69 ± 0.20   500 Schulze 2005 
Results are expressed as mean ± standard deviation (SD). NM = not mentioned in the article. 
AccQ, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate; CE, capillary electrophoresis; ELISA, enzyme-linked 
immunosorbent assay; GC, gas chromatography; HPLC, high performance liquid chromatography; LC, liquid 
chromatorgraphy; MS, mass spectrometry; NDA, naphthalene-2,3-dicarboxaldehyde; OPA, ortho-phthaldialdehyde. 
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In most cases, purified samples are usually derivatized using o-phthaldialdehyde 
(OPA) reagent before injection onto the HPLC column, although underivatized 
dimethylarginines have also been quantified in plasma using ultraviolet detection at 200 
nm (MacAllister et al. 1996). Other derivatization reagents that have been successfully 
used for the dimethylarginines are naphthalene-2,3-dicarboxaldehyde (NDA) (Marra et 
al. 2003), 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AccQ) (Anderstam et 
al. 1997; Heresztyn et al. 2004), 4-fluoro-7-nitro-2,1,3-benzoxadiazole (Nonaka et al. 
2005) and phenyl isothiocyanate (Ueno et al. 1992). The major advantages of the most 
widely used OPA are its rapid reaction at room temperature and at +4ºC as well as the 
fact that OPA itself is non-fluorescent, leading to comparatively clean chromatograms. 
Both 2-mercaptoethanol and 3-mercaptopropionic acid can be used as the thiol reagents 
needed in the OPA derivatization reaction. Fluorescence detection of OPA is performed 
at excitation and emission wavelengths of 340 and 455 nm, respectively. 
Inclusion of an internal standard is necessary for sample purification steps and 
derivatization reactions before chromatographic separation of the analytes. An optimal 
internal standard should not be present in biological samples, although it is not always 
possible to meet this requirement. This may lead to systematic errors in the 
quantification, since the total concentration of the internal standard, i.e. endogenous 
plus added, is unknown and varying within individual samples. L-homoarginine and L-
NMMA are the most widely used internal standards in dimethylarginine HPLC analysis 
(Chan et al. 2000; Pi et al. 2000; Böger et al. 2001; Teerlink et al. 2002). Although L-
NMMA is an endogenous methylated amino acid which is catalyzed by PRMT-1 in the 
same reaction where ADMA is formed during protein degradation, its plasma 
concentration is more than tenfold lower than that of ADMA (Vallance et al. 1992). 
Only Nω-propyl-L-arginine, which is also used as an internal standard (Marra et al. 
2003), does not occur endogenously. A recently published study has used a new non-
endogenous internal standard, monoethylarginine, in an HPLC assay with OPA-
derivatization. It was claimed that monoethylarginine should replace the endogenous 
internal standard L-NMMA (Blackwell et al. 2009). 
The choice of the column, mobile phase composition and pH, and column 
temperature are all critical for the chromatographic separation of ADMA, SDMA and 
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L-arginine. Chromatographic separation is usually performed by reversed-phase 
chromatography using isocratic or gradient elution. Phenyl and C18 columns are 
commonly used in HPLC based assays of dimethylarginines. In many studies, octadecyl 
silane C18 or C20 columns have been used and the running buffer has been phosphate 
or acetate buffer combined with methanol as the solvent component (Teerlink et al. 
2002; Heresztyn et al. 2004; Zhang and Kaye 2004). Additionally, tetrahydrofuran has 
been used in the mobile phase and its inclusion can be crucial in achieving a successful 
separation (Pettersson et al. 1997; Chu et al. 2003; Eid et al. 2003; Jiang et al. 2004). In 
phenyl-based columns, the mobile phase most often is citric acid with methanol 
(Kielstein et al. 1999; Böger et al. 2000b). The pH of the buffers in mobile phase is in 
the range of 6.0-7.1 with the column kept at room temperature or higher (27-42ºC), 
during the analysis. The total running time has varied from 35 min to 78 min. In these 
methods, detection limit was 0.025-0.1 μM for ADMA and SDMA with coefficient 
variation (CV) of less than 5-7% being achieved. 
Recently, new mass spectrometry (MS) -based methods have been described for L-
arginine, ADMA and SDMA (Vishwanathan et al. 2000; Huang et al. 2004; Xu et al. 
2004; Kirchherr and Kühn-Velten 2005; Schwedhelm et al. 2005; Martens-Lobenhoffer 
and Bode-Böger 2006). In addition, it is also possible to measure L-citrulline, which is 
involved in L-arginine-nitric oxide pathway, in the same run (Martens-Lobenhoffer and 
Bode-Böger 2003). Mass spectrometry increases the selectivity of the procedure 
because analytes are identified due to their characteristic molecular mass-to-charge 
(m/z) ratio, by their fragmentation pattern, as well as by their retention times in HPLC. 
Due to of the superior selectivity of MS methods, sample preparation can be reduced to 
protein precipitation for plasma and dilution for urine samples. Commercially available 
or synthesized isotope-labeled L-arginine or ADMA analogues were used as internal 
standards. L-arginine and dimethylarginines were separated in their underivatized 
(Vishwanathan et al. 2000; Huang et al. 2004; Kirchherr and Kühn-Velten 2005) or 
derivatized states (Schwedhelm et al. 2005; Martens-Lobenhoffer and Bode-Böger 
2006) and quantification was carried out by electrospray (Vishwanathan et al. 2000; 
Kirchherr and Kühn-Velten 2005; Martens-Lobenhoffer and Bode-Böger 2006) or 
atmospheric pressure chemical ionization (Huang et al. 2004) techniques. At their best, 
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mass spectrometry based methods provided a high sample throughput with short 
analysis times (4 min) with sharp peaks in the chromatograms (Schwedhelm et al. 
2005). 
In gas chromatography (GC)-based MS methods, it is not possible to analyze polar 
amino acids, such as L-arginine or dimethylarginines, unless they are derivatized 
(Tsikas et al. 2003; Albsmeier et al. 2004). Plasma sample cleanup has been performed 
by ultrafiltration or by protein precipitation, and the derivatization has consisted of 
esterification and pentafluoropropionic anhydride conversion. For L-arginine, there is a 
commercially available internal standard [15N2]-Arg but for ADMA, internal standard 
has to be synthesized. Both GC-MS and GC-MS/MS methods have used Optima-17 
capillary column separation and negative-ion chemical ionization detection (Tsikas et 
al. 2003; Albsmeier et al. 2004). The methods were reported to be accurate and stable 
with no interference from endogenous substances being observed in the 
chromatograms.
2.3.2 Immunological methods 
A newly developed ELISA test is based on competitive enzyme linked immunoassay 
with polyclonal antibodies. This assay allows the measurement of ADMA in human 
plasma or serum (Schulze et al. 2004). Acylation is needed for sample preparation 
before the ELISA assay, and only a small sample volume (20 μl) is required for the test. 
The amount of antibody bound to the plate well is determined by the reaction of 
tetramethylbenzidine with the horseradish peroxidise that is coupled to the secondary 
antibody. The intensity of the developing colour is inversely proportional to the amount 
of ADMA in the sample and measured by reading the optical density of the wells at 450 
nm in a microtiter plate reader. This ELISA test has been validated by comparing it 
with the LC-MS/MS technique and the correlation was good (R=0.984, n=29). Cross-
reactivities with other L-arginine analogues present in human plasma and serum have 
been found to be negligible (L-NMMA 1.0%, SDMA 1.2%, L-arginine <0.02%). This 
ELISA test has a linear range between 0.1 and 3 μM for ADMA in human serum and 
plasma. 
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2.4 ADMA in health and disease 
2.4.1 Biological variation in ADMA plasma concentration 
ADMA and SDMA concentrations are tightly controlled in normal healthy population. 
It has been demonstrated that ADMA has a very narrow concentration distribution in 
plasma (Teerlink 2005b). In normal healthy individuals, the concentrations are usually 
low (0.40-0.77 μM, n=238) (Hov et al. 2007), and at the most in the low micromolar 
range in diseased states. Blackwell et al. (2007) have recently shown that ADMA and 
SDMA exhibit low intra-individual biological variation (7.4% and 5.8%, respectively) 
when measured once a week for 20 weeks. Inter-individual variation for ADMA and 
SDMA was 9.6% and 14.7%, respectively. They also found that plasma ADMA and 
SDMA concentrations were normally distributed. Furthermore, it has been noted that 
ADMA concentration increases linearly with age (Miyazaki et al. 1999; Schulze et al. 
2005; Marliss et al. 2006) and this finding may suggest that there are larger variations 
in ADMA concentration if the study group exhibits a broad age range. On the other 
hand, large population based studies have revealed conflicting results about whether 
there are differences between genders or age groups in the ADMA concentrations 
(Schulze et al. 2005; Blackwell et al. 2007; Teerlink 2007). 
2.4.2 Function of ADMA 
ADMA is able to inhibit vascular NO production by inhibiting all three isoforms of 
NOS within the concentration range found in patients with vascular diseases (Böger 
2004). It has been observed that acute systemic administration of ADMA to healthy 
men elicits a transient fall in heart rate and cardiac output and increases vascular 
resistance (Achan et al. 2003). Smith et al. (2005) have examined the mechanisms by 
which low concentrations of ADMA produce adverse effects on the cardiovascular 
system. They treated human endothelial cells from coronary artery with high ADMA 
concentrations and measured expression of the genes involved in cell cycle regulation, 
cell proliferation, DNA repair, regulation of transcription and metabolism. Significant 
changes in genes expression of more than 50 genes were found in the endothelial cells. 
Interestingly, with pathophysiological concentrations of ADMA (2 μM), the change 
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was seen in endothelial cell gene expression even in the presence of very high L-
arginine concentrations (300 μM). These results were confirmed in an in vivo study 
with DDAH-1 heterozygous knockout mice. 
2.4.3 ADMA and endothelial function 
In recent years, endothelial function has been estimated widely by the non-invasive 
brachial artery flow-mediated dilatation technique. Endothelium plays a role in the 
vascular tonus control through NO generated by NOS. Normally NO increases blood 
flow by acting as a signal resulting in vasodilatation. Endothelial dysfunction is 
characterized by several pathological conditions, such as altered anti-coagulant and 
anti-inflammatory properties of the endothelium, impaired modulation of vascular 
growth and dysregulation of vascular remodelling. Recent genetic and chemical-
biological approaches provide compelling evidence that loss of DDAH-1 function as 
studied in Ddah1+/– mice resulted in increased ADMA concentrations and thereby 
disrupted vascular NO signalling (Leiper et al. 2007). Endothelial dysfunction may also 
be caused by decreased availability of its substrate, L-arginine, or cofactors, or a change 
in cellular signalling (Endemann and Schiffrin 2004; Xiao et al 2009). However, 
ADMA is considered as a key factor contributing to endothelial dysfunction and in 
several clinical studies an increased ADMA concentration has been associated with 
endothelial dysfunction in patients with hypertension, hypercholesterolemia and heart 
failure (Böger et al. 1998; Usui et al. 1998; Surdacki et al. 1999). In the Cardiovascular 
Risk in Young Finns Study, it has also been demonstrated that at the normal population 
level elevated plasma ADMA concentrations are associated with decreased brachial 
FMD (Juonala et al. 2007). It is also evident that endothelial dysfunction is closely 
associated with oxidative stress and one proposed mechanism is that reactive oxygen 
species increase the comsumption of NO (Guzik et al. 2000; Kalinowski and Malinski 
2004). Recently, it has also been suggested that ADMA in addition to inhibiting NO 
modulation, directly induces oxidative stress (Böger et al. 2000b). Increased oxidative 
stress is suggested to disminish DDAH activity which leads to accumulation of ADMA 
(Ito et al. 1999, Palm et al. 2007). 
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2.4.4 ADMA and cardiovascular diseases 
Asymmetric dimethylarginine is now considered to be an important biomarker in the 
assessment of cardiovascular risk (reviewed in Siroen et al. 2006b; Böger et al. 2009). 
Several studies have shown that plasma levels of ADMA are increased in patients with 
vascular disease, or with risk factors for vascular disease (Böger et al. 1998; Valkonen 
et al. 2001; Lu et al. 2003; Cooke 2004). NO is the most potent endogenous vasodilator 
and thus any impairment of NO synthesis or bioactivity may increase the risk of 
vascular disease. When the NOS pathway becomes dysregulated, its vasoprotective 
functions are lost, and the NOS pathway may even contribute to vascular 
pathophysiology. In mice, a chronic infusion of ADMA has induced atherosclerosis 
(Suda et al. 2004). In humans, the ADMA concentration in plasma correlates with 
markers of subclinical atherosclerosis, such as carotid artery intima media thickness 
(Zoccali et al. 2002). Derangements of the NOS pathway may be categorized as 
reductions in the NO half-life, altered sensitivities to NO, as well as changes in NOS 
expression or NOS activity. NO also acts as an endogenous inhibitor of platelet 
aggregation (Azuma et al. 1986; Radomski et al. 1987). Furthermore, NO inhibits the 
adhesion of monocytes and leucocytes in the healthy vascular endothelium (Kubes et al. 
1994, Tsao et al. 1994) – an effect that once disturbed precedes the migration of 
inflammatory cells into the vascular wall at sites that later become plaques. NO also 
inhibits the proliferation of vascular smooth muscle cells (Garg and Hassid 1989) and 
reduces the vascular release of superoxide radicals (Violi et al. 1999) that are involved 
in inflammatory and cytotoxic processes, and it also inhibits low-density lipoprotein 
(LDL) oxidation (Hogg et al. 1993). 
Endogenous inhibitors of NOS are responsible for endothelial vasodilator 
dysfunction in individuals with coronary and peripheral arterial disease, as well as those 
with risk factors, such as hypercholesterolemia, hypertension, hyperhomocysteinemia 
and insulin resistance. In experimental animal models, ADMA levels start to increase 
very rapidly after the induction of dietary hypercholesterolemia. Even though at that 
time, no overt atherosclerotic lesions can be found macroscopically (Bode-Böger et al. 
1996). Similarly, elevated ADMA plasma levels have been observed in clinically 
healthy human subjects with isolated hypercholesterolemia and other cardiovascular 
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risk factors (Böger et al. 1998; Vlamidirova-Kitova et al. 2008). Several animal and 
clinical studies have also demonstrated a strong association between plasma total 
homocysteine, plasma ADMA, and endothelial dysfunction (Böger et al. 2000a; Böger 
et al. 2001; Yoo and Lee 2001; Holven et al. 2003; Selley 2003; Stühlinger et al. 2003; 
Sydow et al. 2003). It has been suggested that ADMA may be a mediator of the 
atherogenic effects of homocysteine (Holven et al. 2002). These data suggest that 
ADMA is an early marker of the initial stages of atherogenesis, and thus may be useful 
in devising the primary prevention to assess a patient’s total cardiovascular risk and to 
supplement the information generated by traditional risk factors. 
2.4.5 ADMA in other diseases 
Some examples of ADMA concentrations in different diseases are collected in Table 2. 
More detailed information about some diseases is discussed below. In seriously ill 
patients, the level of methylated arginines may be considerably elevated by the 
unfavourable combination of an increased production of dimethylarginines as a result 
of increased protein turnover, e.g. catabolic state, synthesis of acute phase proteins, and 
decreased elimination as a result of impaired renal and hepatic clearance capacities 
(Nijveldt et al. 2003c). Additionally, elevated plasma ADMA levels are known to be 
associated with cardiovascular complications such as stroke, congestive heart failure 
and peripheral arterial disease (Böger et al. 1997; Usui et al. 1998; Yoo and Lee 2001). 
Furthermore, in patients with cardiovascular disease, end-state renal disease, or some 
other serious illnesses, elevated plasma ADMA concentrations independently predict 
progression of atherosclerosis, future vascular events and/or overall mortality 
(Valkonen et al. 2001; Zoccali et al. 2001; Lu et al. 2003; Aucella et al. 2009). 
The kidneys play an important role in the elimination of dimethylarginines from the 
body and a significant elevation of the plasma ADMA levels is observed in patients 
with end-stage renal failure (Vallance et al. 1992; Zoggali et al. 2001; Billecke et al. 
2009). Elevated ADMA levels and endothelial dysfunction may in part be responsible 
for the highly elevated cardiovascular morbidity and mortality in patients with chronic 
renal failure (Kielstein et al. 1999). Additionally, in patients with end-state renal 
disease, ADMA concentrations have emerged as the second strongest predictor of all-
30
cause mortality after age, outweighing other established risk factors such as 
hypertension, diabetes, hypercholesterolemia and smoking (Zoggali et al. 2001; 
Mallamaci et al. 2005). 
Table 2. Mean plasma or serum ADMA concentrations in different disease states.
Disease state ADMA (μM) Number of  Reference 
 Controls Cases controls+cases  
Coronary heart disease 0.47 ± 0.12 0.66 ± 0.17 139 + 70 Valkonen et al. 2001 
Coronary heart disease 0.44 ± 0.09 0.47 ± 0.12 46 + 51 Lu et al. 2003 
Chronic kidney disease 0.61 ± 0.13 1.04 ± 0.17 9 + 13 Wahbi et al. 2001 
Chronic kidney disease 1.4 ± 0.7 4.2 ± 0.9 16 + 44 Kielstein et al. 2002 
Hypercholesterolemia 1.03 ± 0.09 2.17 ± 0.09 31 + 49 Böger at al. 1998 
Hypercholesterolemia 1.3 ± 0.2 2.1 ± 0.2 18 + 24 Chan et al. 2000 
Liver cirrhosis 0.58 ± 0.05 1.12 ± 0.08 7 + 20 Lluch et al. 2004 
Acute liver failure 0.37 ± 0.02 1.75 ± 0.3 10 + 10 Mookerjee et al. 2007 
End-stage renal disease 0.42 ± 0.02 0.82 ± 0.03 16 + 18 Billecke et al. 2009 
Cerebral infarction 0.93 ± 0.32 1.46 ± 0.77 35 + 27 Yoo et al. 2001 
Recurrent cerebral 
infarction 
0.93 ± 0.32 2.28 ± 1.63 35 + 25 Yoo et al. 2001 
Hypertension 0.43 ± 0.12 0.59 ± 0.13 47 + 16 Päivä et al. 2002 
Hypertension 0.42 ± 0.02 0.60 ± 0.04 16 + 18 Billecke et al. 2009 
Diabetes type 1 0.40 ± 0.06 # 0.46 ± 0.08 # 175 + 397 Lajer et al. 2008 
Diabetes type 1 0.43 § 0.50 § 50 + 20 Cighetti et al. 2009 
Pre-eclampsia 0.81 2.7 43 + 10 Savvidou et al. 2003
Polycystic ovary syndrome 0.652 ± 0.040 0.746 ± 0.025 30 + 160 Charitidou et al. 2008 
Polycystic ovary syndrome 0.09 ± 0.02 0.17 ± 0.02 22 + 44 Ozgyrtas et al. 2008 
Results are expressed as mean ± SD. 
# Controls have diabetes without microalbuminuria and cases have diabetes with nephropathy. 
§ Concentration is expressed as median. 
The liver is also a critical organ in regulating plasma ADMA concentration and 
dysfunction of the liver may disturb normal ADMA metabolism (Nijveldt et al. 2003a; 
Siroen et al. 2005; Mookerjee et al. 2007). In patients undergoing liver transplantation, 
the preoperative ADMA concentrations in plasma were highly elevated, but decreased 
significantly after the operation (Siroen et al. 2004). Additionally, in patients with acute 
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rejection, ADMA levels were higher than those in nonrejectors. ADMA may also be of 
significance in the pathophysiology of liver cirrhosis, since it has been shown that 
ADMA concentrations are elevated in patients with alcoholic cirrhosis (Lluch et al. 
2004 and 2006). However, the exact mechanism of how ADMA is involved in the 
pathophysiology of liver cirrhosis is not known. 
There is also evidence that the lung can generate a significant amount of ADMA and 
therefore it may directly contribute to interstitial and circulating ADMA concentration 
(Bulau et al. 2007). In recent studies, dysregulated arginine methylation has been 
shown to contribute to the pathogenesis of several chronic pulmonary diseases such as 
pulmonary arterial hypertension and pulmonary fibrosis (Zakrzewicz and Eickelberg 
2009). 
In diabetic patients, there have been controversial results of studies showing 
elevated, normal or even decreased circulating ADMA concentration (Päivä et al. 2003; 
Krzyzanowska et al. 2007a; Lajer et al 2008; Cighetti et al. 2009), although it has been 
recently reported that ADMA levels above the median may predict an increased risk of 
fatal and non-fatal cardiovascular events in type 1 diabetic patients with nephropathy 
(Lajer et al. 2008). Furthermore, Krzyzanowska et al. (2007b) have shown that an 
elevated ADMA concentration was associated with an increased risk of cardiovascular 
events also in type 2 diabetic patients with albuminuria. It has been also suggested that 
ADMA plays an important role as a risk marker in insulin resistance (Chan and Chan 
2002; Sydow et al. 2005), and pharmacological agents that improve insulin sensitivity 
are able to lower the plasma ADMA concentration (Stühlinger et al. 2002; Wakino et 
al. 2005). 
2.5 Reproduction and ADMA 
2.5.1 Effect of menstrual cycle changes on ADMA 
Giusti et al. (2002) evaluated the concentrations of circulating NO throughout the 
menstrual cycle in healthy women and they found that the NO concentration 
significantly declined from the early follicular phase (day 7) towards the luteal phase 
(day 21). It is known that exogenous estrogen has a lowering effect on circulating 
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ADMA levels (Holden et al. 2003) and that the plasma ADMA concentration correlated 
with age in women but not in men (Hov et al. 2007). Cevik et al. (2006) measured the 
ADMA concentrations at a low menstrual estrogenic stage and at ovarian 
hyperstimulation state when the estrogen concentration was 20-fold higher. They found 
that ADMA was lower in women with high plasma estrogen levels than that in women 
with low estrogen levels. Furthermore, there is evidence that the use of oral 
contraceptives reduced significantly the ADMA concentration and the delivery method 
of OC was important since transdermally administered estrogen had no effect on the 
ADMA concentration (Verhoeven et al. 2006 and 2007). 
Recently, it has been found that the ADMA concentration is significantly higher in 
women above 45 years of age in comparison with women younger than that age (Hov et 
al. 2007) and postmenopausal hormone therapy has been reported to reduce the ADMA 
concentration (Post et al. 2003; Teerlink et al. 2003; Verhoeven et al. 2006). 
The polycystic ovary syndrome (PCOS) is the most common hormonal disorder 
causing menstrual abnormalities among women of reproductive age and is a leading 
cause of infertility (Diamanti-Kandarakis and Panidis 2006). It is characterized by 
disturbances in gonadotropin secretion, steroidogenesis and increased resistance to 
insulin. Women with PCOS have an increased risk of metabolic and cardiovascular 
morbidity (Dahlgren et al. 1992) and PCOS is also associated with endothelial 
dysfunction (Paradisi et al. 2001). An elevated ADMA concentration has been detected 
in women with PCOS in comparison with healthy control women (Charitidou et al. 
2008; Ozgurtas et al. 2008). In these PCOS studies, the ADMA concentration was 
significantly decreased by natural or synthetic estrogen treatment combined with anti-
androgen therapy. Estrogen treatment may decrease the serum ADMA concentration in 
PCOS patients by several mechanisms, such as stimulating NO production, increasing 
ADMA degradation by up-regulation of DDAH activity, and having a protective effect 
on DDAH activity against oxidative stress (Charitidou et al. 2008). 
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2.5.2 ADMA and pregnancy 
2.5.2.1 ADMA in normal pregnancies 
Normal pregnancy is characterized by enhanced vasodilatation mainly mediated by 
endothelial NOS and the increased production of NO (Faber-Swensson et al. 2004). 
Additionally, there are several changes occurring during pregnancy e.g. the appearance 
of hypercholesterolemia, insulin resistance and an upregulation of the immune system 
which may in normal non-pregnant conditions be detrimental to health (Aagaard-Tillery 
et al. 2006; Saarelainen et al. 2006; Zavalza-Gomez et al. 2008). Hypercholesterolemia 
during pregnancy may be associated with the increased production of estrogen 
(Kvasnicka et al. 1997) and the maintenance of adequate supply of nutrients to mother 
and fetus. Furthermore, the immune system plays a vital role in pregnancy and 
cytokines are involved in both the maintenance of pregnancy and the onset of normal 
labor (Elenkov et al. 1999). In normal pregnancy, ADMA and SDMA levels are 
decreased in comparison with the levels found in non-pregnant females (Holden et al. 
1998; Pettersson et al. 1998; Ellis et al. 2001; Savvidou et al. 2003). The reduced 
circulating ADMA concentration may be due to increased DDAH activity induced by 
estrogen, increased renal clearance or hemodilution typical of normal pregnancy. A 
very recent study investigated the relationship between maternal risk factors, neonatal 
demographic features and ADMA concentration and reported that the most significant 
factor affecting umbilical vein ADMA concentrations seemed to be perinatal hypoxia 
(Kul et al. 2009). 
2.5.2.2 ADMA in complicated pregnancies 
Gestational diabetes mellitus (GDM) develops in 3-6% of all pregnant women being
characterized by a pronounced decrease in insulin sensitivity leading to higher plasma 
insulin levels and abnormalities in glucose tolerance during pregnancy (Alwan et al. 
2009). Women with previous GDM have a high risk of developing impaired glucose 
tolerance or manifest type 2 diabetes mellitus in the future (Kim et al. 2002). A recent 
study by Telejko et al. (2009) has shown that there was no significant difference in the 
ADMA concentration between healthy pregnant controls and pregnant women with 
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GDM. Nonetheless it has been previously demonstrated that high glucose 
concentrations can induce an impairment of DDAH activity, thereby slowing ADMA 
degradation (Lin et al. 2002). In an earlier study, it was revealed that high ADMA 
concentrations after delivery are associated with deterioration in glucose tolerance in 
women with previous GDM. However in GDM pregnancies, circulating ADMA 
concentrations decreased after a median follow-up of 2.75 years after delivery 
(Mittermayer et al. 2007).
Preeclampsia is considered to be one of the most serious complications occurring in 
pregnancy being responsible for 5-8% of all gestation complications (Lain and Roberts 
2002). The exact pathophysiology leading to preeclampsia is unknown, but it has been 
suggested that the invading trophoblast leads to a hypoperfused placenta which then 
releases factors into the maternal circulation eventually leading to maternal endothelial 
dysfunction (Pijnenborg et al. 1983; Rajagopal et al. 2003). It has been shown that 
plasma ADMA concentrations can become elevated in preeclamptic pregnancies 
(Fickling et al. 1993). In addition, it has been suggested that the high molar ratio of 
ADMA/SDMA is evidence of an impairment of DDAH activity (Savvidou et al. 2003) 
and furthermore, that it is the reduced L-arginine concentrations, rather than an 
increased ADMA level, which contributes to the development of preeclampsia (Kim et 
al. 2006). L-arginine levels have been found to be significantly lower in preeclamptic 
women in comparison with normal pregnant women, but there were no significant 
differences in ADMA levels between normal and preeclamptic women (Kim et al. 
2006). However, there are differences in both ADMA and L-arginine levels between 
normal and preeclamptic pregnancies, and these may be attributable to several reasons 
such as differences in blood pressure, renal function, ethnic groups and sample analysis 
techniques (Petersson et al. 1998; Savvidou et al. 2003; Kim et al. 2006; Siroen et al. 
2006a). ADMA concentrations have also been measured from fetal samples and only 
SDMA concentration was higher in the preeclampsia group compared to the controls. It 
was reported that the median ADMA concentration was three times higher in the fetal 
circulation than in the maternal plasma, but there was no difference between the 
preeclampsia group and the control group (Braekke et al. 2009). 
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3 AIMS OF THE STUDY 
In the present series of studies, the aim was to study if there is an association 
between ADMA and flow-mediated dilatation or with factors that are involved in 
normal pregnancy, such as hypercholesterolemia and changes in the immune 
system. 
The specific aims of the studies were as follows: 
I To devise and validate a suitable analysis method based on previously published 
HPLC methods for L-arginine, ADMA and SDMA concentrations. The 
performance of the ADMA ELISA assay was also evaluated. 
II To investigate the effect of hormonal cyclic changes on levels of ADMA and its 
related compounds in healthy non-pregnant women with and without hormonal 
contraceptive use. 
III To investigate the relationship between ADMA and flow-mediated dilatation in 
normal pregnancy. 
IV To measure the concentration of L-homoarginine concentration in non-pregnant 
women and in normal pregnancy. To investigate whether the ADMA 
concentration is related to the level of L-homoarginine. 
V To study whether there is an association between serum levels of ADMA and 
proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-
α (TNF-α) and C-reactive protein in normal pregnancy. 
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4 SUBJECTS AND METHODS 
4.1 Study subjects 
Blood samples for ADMA HPLC method validation (I) were collected from healthy 
volunteers. Samples (n=55) for ADMA HPLC and ELISA method comparison were 
collected from the Research Institute of Public Health, University of Kuopio. 
4.1.1 Subjects from The Cardiovascular Risk in Young Finns Study (II - V) 
Non-pregnant women and women with normal pregnancy were derived from The 
Cardiovascular Risk in Young Finns Study (Åkerblom et al. 1985; Raitakari et al. 2008) 
which is an ongoing 5-center follow-up study of risk factors of atherosclerosis in 
Finnish children and adolescents. The participants were randomly chosen from a 
national population register, as previously described (Raitakari et al. 2008). At the 
beginning of the study in 1980, there were 3 596 participants. In the follow-up study in 
2001, 2 283 young adults were studied in the age range from 24 to 39 years (Juonala et 
al. 2004). The menstrual cycle phase at the sampling moment and the use of oral 
contraceptives were inquired from the participants. Menstrual cycle was divided into 
four different phases; early follicular phase (1-7 days from the beginning of 
menstruation), late follicular phase (8-14 days from the beginning of menstruation), 
early luteal phase (15-19 days from the beginning of menstruation) and late luteal phase 
(20-40 days from the beginning of menstruation). Contraceptive types were divided into 
4 categories; constant estrogen dose with low progestin dose (n=110), constant estrogen 
dose with high progestin dose (n=120), progestin alone (n=10) and combination 
preparation with changing doses (n=68). All subjects provided written informed consent 
before participating in the study. The local ethics committee in Turku University 
approved The Cardiovascular Risk in Young Finns Study. Summary of study subjects in 
different studies are collected to Table 3. 
4.1.2 Subjects from The Complicated Pregnancy Study (IV - V) 
Subjects from The Complicated Pregnancy Study were recruited from Kuopio 
University Hospital area and there were women with normal and complicated 
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pregnancies with the followup organized through 2004-2007 from the third trimester of 
pregnancy to the postpartum period (4-7 months). Age of the studied subjects was 
ranging from 21 to 39 years. There were subjects with normal uncomplicated 
pregnancies who were studied once in the third trimester and 79% of them were also 
seen at 3 months postpartum. These groups were used to enhance the information 
obtained from The Cardiovascular Risk in Young Finns Study on what would happen to 
the concentration of ADMA and its related compounds a few months after delivery. The 
Complicated Pregnancy Study was approved by the Research Ethics Committee of the 
Kuopio University Hospital. Summary of study subjects in different studies are 
collected to Table 3. 
Table 3. Summary of study subjects in different studies. 
Subjects    Number of  Original 
      participants publication 
Subjects from The Cardiovascular Risk in Young Finns Study 
Non-pregnant women       
 without OC use         761  II 
 with OC use         318  II 
Non-pregnant women          61  III-V 
Pregnant women 
 1. trimester ( 14 weeks)          13  III-V 
 2. trimester (15–27 weeks)          22  III-V 
 3. trimester ( 28 weeks)          23  III-V 
Subjects from The Complicated Pregnancy Study in Kuopio 
Pregnant women 
 3. trimester ( 28 weeks)          19  IV-V 
 after delivery           15  IV-V 
OC, oral contraceptives. 
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4.2 Analysis methods 
4.2.1 Blood samples and basic measurements of study subjects 
Venous blood samples were drawn for laboratory assays after a 12-h overnight fast. The 
samples were centrifuged at 2000g for 10 min and the serum or plasma was separated 
and stored frozen at -70°C until analysis. The height, weight and waist circumference of 
the subjects were measured, and body mass index (BMI) was calculated 
(weight/height2). Glomerular filtration rate (GFR) was calculated by the Cockcroft-
Gault formula (Cockcroft and Gault 1976). Blood pressure was measured with a 
sphygmomanometer. In The Cardiovascular Risk in Young Finns Study, the basic 
measurements of analytes in clinical chemistry (lipids, glucose, creatinine and high 
sensitive C-reactive protein (hsCRP)) were conducted in Turku. In The Complicated 
Pregnancy Study, the basic measurements of analytes in clinical chemistry (lipids, 
glucose, creatinine and hsCRP) were undertaken in Kuopio University Hospital. All 
cytokine measurements were analyzed in Kuopio University Hospital. ADMA 
measurements in studies I and III-V were done in Kuopio and in study II they were 
analyzed in National Institute of Health and Welfare in Helsinki. 
4.2.2 ADMA HPLC methods (I-V) 
In studies I and III-V, the analysis method for ADMA, SDMA, L-arginine and L-
homoarginine levels in human serum or plasma was set up according to the method 
described by Teerlink et al. (2002) with minor modifications and it is based on HPLC 
technology and fluorescence detection. HPLC analysis was carried out on a Merck 
Hitachi liquid chromatography system (Hitachi, Tokyo, Japan) consisting of a gradient 
pump (D-6200), an autosampler (AS-4000) and a fluorescence detector (F1000). Data 
acquisition and analysis were performed using D-7000 HPLC System Manager software 
(Hitachi, Tokyo, Japan). 
In comparison to the original ADMA method (Teerlink et al. 2002), our HPLC 
method had longer total run time (38 vs. 30 min) and lower acetonitrile concentration 
(35 vs 50 vol.%) for column washing after elution of the last analyte. The injection 
volume was twice as great (40 vs 20 μl) and the autosampler derivatized every sample 
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just before each HPLC run instead of derivatization of all purified samples at the same 
time. 
One-point calibration was used and the standard contained 21 μM L-arginine 
(Calbiochem, Merck Biosciences, Darmstadt, Germany), 2 μM L-homoarginine (Fluka, 
Buchs, Switzerland).), 3 μM ADMA (NG,NG-dimethyl-L-arginine, Sigma, St. Louis, 
MO, USA) and 2 μM SDMA (NG, NG’ -dimethyl-L-arginine, Calbiochem, Merck 
Biosciences, Darmstadt, Germany). L-NMMA (NG-monomethyl-L-arginine, Fluka, 
Buchs, Switzerland) was used as an internal standard. A plasma pool (58.6 ± 4.3 μM for 
L-arginine, 1.2 ± 0.03 μM for L-homoarginine, 0.643 ± 0.029 μM for ADMA and 0.654 
± 0.028 μM for SDMA) was used as the quality control. 
Prior to analysis, the standards, quality controls and samples were extracted on Oasis 
MCX solid phase extraction cartridges (Waters, Milford, MA, USA). Briefly, standards, 
quality controls and samples (200 μl) were mixed with 100 μl internal standard L-
NMMA (6 μM) and 700 μl phosphate buffered saline, pH 7.2 and then applied onto the 
columns. The columns were washed with 1 ml of 100 mM hydrochlorid acid and 1 ml 
of methanol. Dimethylarginines were eluted with 1 ml ammonia-water-methanol 
(10:40:50, v/v). The eluents were dried under nitrogen (+55 °C) and dissolved in 100 μl 
ion exchanged water (Milli Q, Millipore, Billerica, MA, USA) for HPLC analysis. 
Standards, quality controls and samples (100 μl) were incubated for 2 min with the 
100 μl OPA reagent (1 mg/ml OPA in borate buffer, pH 9.5, containing 0.1 vol.% 3-
mercaptopropionic acid) before automatic injection (40 μl) into the HPLC. The OPA-
derivatives of ADMA and internal standard were separated on Symmetry C18 column 
(4.6 x 150 mm, 5 μm, Waters, Milford, MA, USA) with the fluorescence monitor set at 
λex = 340 nm and λem = 455 nm. The column temperature was kept at +30 °C. 
Standards, quality controls and samples were eluted from the column with 50 mM K-
phosphate buffer, pH 6.5 and 8.7 vol.% acetonitrile, at a flow rate of 1.1 ml/min. After 
elution of the last analyte, the column was washed with a stronger solvent (35 vol.% 
acetonitrile from 24 to 29 min). After washing, the column was equilibrated for 8 min 
with separation buffer, resulting in a total run time of 38 min. L-arginine was analyzed 
with the same method but in that case, the injection volume was 10 μl and the total run 
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time was shorter (33 min). The retention times were as follows: L-arginine (10.52 ± 
0.13 min), internal standard, L-NMMA, (14.87 ± 0.22 min), L-homoarginine (16.85 ± 
0.25 min), ADMA (19.76 ± 0.29 min) and SDMA (20.89 ± 0.30 min). 
In study II, the HPLC method (Juonala et al. 2007) was also modified from the assay 
described by Teerlink et al. (2002). In this method, proteins were precipitated before 
solid phase extraction as distinct from the method used in other studies. The intra- and 
interassay CVs of the plasma pool for ADMA, SDMA, L-homoarginine and L-arginine 
are shown in Table 4. 
Table 4. Characteristics of ADMA and related compounds analysis methods. 
Coefficient of variation Analyte Source of 
reagents 
Principle 
of assay Intra-assay Interassay 
Method used in studies I, III-V 
ADMA 2.5% 4.2% 
SDMA 5.6% 3.7% 
L-arginine 2.5% 2.8% 
L-homoarginine 
In-house HPLC 
1.4% 2.9% 
Method used in study II 
ADMA 7.5% 12.9% 
SDMA 5.7% 10.6% 
L-arginine 
In-house HPLC 
6.5% 12.1% 
Method used in study I 
ADMA DLD Diagnostika 
GmbH, Germany 
ELISA 19% 9-14% 
ADMA, asymmetric dimethylarginine; ELISA, enzyme-linked immunosorbent assay; HPLC, high 
performance liquid chromatography; SDMA, symmetric dimethylarginine. 
4.2.3 ADMA ELISA assay (I) 
Sample preparation for ELISA assay was done according to the instructions of the 
manufacturer (ADMA-ELISA kit, DLD Diagnostika GmbH, Hamburg, Germany). The 
ADMA-ELISA kit consists of a split-type reaction plate (12 x 8) coated with ADMA, 
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six standards (0-5 μM), rabbit anti-ADMA antiserum, goat anti-rabbit-IgG-peroxidase 
conjugate, tetramethylbenzidine substrate solution, stop solution and wash buffer. 
Acylation was conducted in the 96-well reaction plate supplied with the kit. Standards, 
controls and samples (20 μl) were mixed with 25 μl acylation buffer and 25 μl 
equalizing reagent. Subsequently 25 μl acylation reagent was added and the reaction 
plate was incubated for 30 min at room temperature on an orbital shaker. Diluted 
equalizing reagent (100 μl) was added and the incubation was continued for 45 min 
prior to the assay. In ELISA assay, aliquots (50 μl) of the acylated standards, controls or 
samples were processed according to the instructions of the kit manufacturer. The 
absorbances were measured with a microplate reader (Tecan SPECTRAFluor, Tecan 
Group Ltd., Maennedorf, Switzerland) using a wavelength of 450 nm (reference 
wavelength 620 nm). All samples, controls and standards were analyzed in duplicate. 
4.2.4 Measurement of flow-mediated dilatation (II -IV) 
Brachial artery flow-mediated dilatation was measured by ultrasound according to the 
guidelines (Corretti et al. 2002) and as described earlier (Juonala et al. 2004). 
Ultrasound studies were performed using Sequoia 512 mainframes (Acuson, CA, USA) 
with 14.0 MHz linear array transducers. The segment of the brachial artery above the 
antecubital crease was imaged in the longitudinal plane at rest and during reactive 
hyperemia, induced by a sphygmomanometer cuff, which was placed around the 
forearm, inflated to a pressure of 250 mmHg and deflated after 4.5 minutes. End-
diastolic (incident with the R-wave) arterial diameter was measured at rest (baseline) 
and at 40, 60 and 80 s after cuff release from 5 s ultrasound image sets. The vessel 
diameter response in scans after reactive hyperemia was expressed both as the absolute 
change in diameter (FMD) and as the percentage relative to the resting scan (FMD%). 
The three month between-visit CV was 3.2% and 26.0% for brachial artery diameter 
and for FMD measurements, respectively. 
4.2.5 Measurement of serum lipid, glucose and creatinine concentrations (II - V) 
Lipid analyses from samples of The Cardiovascular Risk in Young Finns Study were 
performed by standard enzymatic methods (Olympus System Reagents, Olympus 
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Diagnostica GmbH, Hamburg, Germany) in a clinical chemistry analyser (AU400; 
Olympus Optical Ltd, Mishima, Japan) (Juonala et al. 2004). Glucose concentrations 
and creatinine concentrations were analyzed by standard methods (Olympus 
Diagnostica GmbH, Hamburg, Germany). 
Lipid analyses from samples of The Complicated Pregnancy Study in Kuopio were 
performed with Konelab 60i Clinical Chemistry Analyzer (Thermo Electron Co, 
Finland). The triglyceride concentration was determined by enzymatic, photometric 
assay (Konelab TRIGLYCERIDES kit, Thermo Electron Co, Finland) and the total 
serum cholesterol concentration was analyzed by enzymatic, photometric assay 
(Konelab CHOLESTEROL kit, Thermo Electron Co, Finland). High-density lipoprotein 
(HDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol were determined by a 
direct, enzymatic, photometric method (Konelab HDL-CHOLESTEROL and Konelab 
LDL-CHOLESTEROL kits, Thermo Electron Co, Finland). Glucose and creatinine 
concentrations were analyzed by standard methods (Konelab 60i Clinical Chemistry 
Analyzer, Thermo Electron Co, Finland). 
4.2.6 Measurement of proinflammatory cytokines (V) 
All serum IL-6 and TNF-α concentrations were measured with a commercially 
available ELISA assay according to the protocol supplied by the manufacturer 
(Quantikine HS Human IL-6 and Quantikine HS Human TNF-α/TNFSF1A 
Immunossay Kits, R&D Systems, Minneapolis, USA). The working range was 0.156–
10 pg/ml for IL-6 and 0.5–32 pg/ml for TNF-α. Calibrators for both IL-6 and TNF-α
assays were analyzed in duplicate but the samples were assayed as single 
measurements. The absorbances in ELISA tests were measured at a wavelength of 490 
nm using a microplate reader (Tecan SPECTRAFluor, Tecan Group Ltd., Maennedorf, 
Switzerland). The TNF-α/IL-6 ratio was calculated and used as an index of Th1/Th2 
response. The detection limits and CVs of the methods are shown in Table 5. 
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4.2.7 Measurement of high sensitive C-reactive protein (II, V) 
Samples from The Cardiovascular Risk in Young Finns Study were analyzed by latex 
immunoturbidometric assay (CRP-UL, Wako Chemicals GmbH, Neuss, Germany) by 
an automated analyzer (Olympus AU400, Tokyo, Japan). 
Samples from Complicated Pregnancy Study in Kuopio were analyzed by a kinetic 
immunoturbidometric method. Serum samples were analyzed by IMMAGE- automated 
analyzer using Beckman Coulter High Sensitivity C-Reactive Protein reagents 
(Beckman-Coulter, Fullerton, CA, USA). The detection limits and CVs of the methods 
are shown in Table 5. 
Table 5. Characteristics of hsCRP, IL-6 and TNF-α analysis methods. 
Coefficient of variation Analyte 
(study) 
Source of  
reagents 
Principle 
of assay  Intra-assay Interassay 
Detection 
limit 
hsCRP 
(study A) 
Wako Chemicals 
GmbH, Germany 
Kinetic immuno-
turbidometric 
 3.3% 
(1.52 mg/l) 
0.06 mg/l 
hsCRP 
(study B) 
Beckman-Coulter, 
USA 
Kinetic immuno-
turbidometric 
 13.5% 
(0.8 mg/l) 
0.2 mg/l 
IL-6 R&D Systems, 
USA 
ELISA 6.5% 14% 0.156 pg/ml 
TNF-α 
(study A+B) 
R&D Systems, 
USA 
ELISA 7.4% 15% 0.5 pg/ml 
Study A: The Cardiovascular Risk in Young Finns Study (Juonala et al. 2006). 
Study B: Complicated Pregnancy Study in Kuopio. 
ELISA, enzyme-linked immunosorbent assay; hsCRP, high sensitive C-reactive protein; IL-6, interleukin-
6; TNF-α, tumor necrosis factor-α.
4.3 Statistical analyses (studies I – V)
In statistical analysis, results were presented as the mean ± standard deviation (SD), 
mean ± standard error of the mean (SEM) or as median values. Comparisons between 
groups were performed with the Kruskal-Wallis test and the non-parametric Mann-
Whitney U test with Bonferroni correction (III - V) or one-way ANOVA test and the t-
test analysis (II). The correlations were calculated by Pearson or Spearman correlation 
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coefficient test. Skewness was assessed using Kolmogorov-Smirnov test. Log-
transformed values were used for L-homoarginine, CRP and GFR because of skewed 
distribution. Linear regression analysis was used for evaluation of association between 
studied groups. Multiple-regression analysis was used to evaluate the independent 
correlations of studied parameters. A computer software program (SPSS 11.5 and 15.0 
for Windows; SPSS Inc., Chicago, IL, USA) was used to analyze the data. A probability 
level of < 0.05 was considered statistically significant. 
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5 RESULTS 
5.1 ADMA HPLC and ELISA assays 
5.1.1 Performance of the HPLC assay 
The performance of the HPLC method published by Teerlink et al. (2002) was good 
after minor modifications in our laboratory as described thoroughly in study I. ADMA 
and SDMA peaks had good separation efficiency under isocratic conditions. The 
representative chromatograms of standard and sample of HPLC method are presented in 
the original publication (I). The linearity of the calibration curve of the HPLC method 
was determined at 7-8 concentrations and it was excellent (Table 3). The lower limit of 
detection and the lower limit of quantitation calculations were based on a signal/noise 
ratio of 3 and a signal/noise ratio of 10, respectively. The performance of the HPLC 
assay is shown in Table 6. 
Table 6. The linearity, the detection limits of the validated ADMA HPLC method and the mean 
recoveries of analytes.
Analyte Concentration 
range (μM) 
Correlation 
coefficient (r) 
Lower limit of 
detection (μM) 
Lower limit of 
quantitation 
(μM) 
Mean 
recovery 
(%) 
ADMA 0.1 - 7.5 0.999 0.1 0.3 95 
SDMA 0.1 - 7.5 0.999 0.1 0.3 95 
L-homoArg 0.1 - 12.9 0.997 0.1 0.3 100 
L-arginine 1.5 - 200 0.999 3 10 113 
ADMA, asymmetric dimethylarginine; L-homoArg, L-homoarginine; SDMA, symmetric 
dimethylarginine. 
There were no significant differences between the ADMA (0.5364 ± 0.015 μM, 
CV=2.7%) or SDMA (0.402 ± 0.010 μM, CV=2.6%) concentrations assayed from 5 
different Vacutainer tube types with and without anticoagulant. In addition in study I, 
mean concentration measurements of plasma (0.607 ± 0.064 μM) versus serum (0.603 ± 
0.072 μM) samples gave similar results for ADMA (n=15). ADMA and SDMA 
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concentrations in EDTA-plasma did not change after four freezing and thawing cycles 
(0.479 ± 0.011 μM, CV=2.4% and 0.462 ± 0.003 μM, CV=0.7%, respectively). The 
ADMA concentrations were stable in EDTA-plasma stored at -20 °C for at least 7 
months (mean concentration 0.661 ± 0.008 μM, CV=1.2%). 
5.1.2 Performance of the ELISA assay and method comparison 
Three ADMA-ELISA kits were used, and standards, kit controls and samples were 
analyzed in duplicate and quality controls were analyzed in every plate. The mean 
concentrations of the kit control 1 was 0.410 ± 0.037 μM and it fitted to the target range 
values (0.24-0.45 μM) in three analyzed plates, whereas the mean concentration of the 
kit control 2 was 1.174 ± 0.165 μM and two results of three did not fit to the target 
range values (0.6-1 μM). The intra-assay CV of the plasma pool (0.436 ± 0.083 μM, 
n=10) was 19% in the ADMA-ELISA assay. The interassay CVs of ADMA (3 different 
plates) was 9% and 14% for kit controls 1 and 2, respectively. 
The ELISA assay was less precise (Table 4) with mean level of the results being 
higher than that of the present HPLC method. In addition, the correlation was poor 
between these assays over the studied concentration range (0.39 to 0.909 μM, 
R2=0.0972) as shown in the original publication (I). 
5.2 ADMA and menstrual cycle phases in women with and without hormonal 
contraceptive use 
Information was available in the menstrual cycle phase of 1079 women with or without 
OC use. The effect of menstrual cycle phases on dimethylarginine and L-arginine 
concentrations was evaluated by dividing the cycle into four phases and comparing the 
concentrations of studied analytes between these phases (Table 7). In non-OC users, 
ADMA, L-arginine and ADMA/SDMA ratio were significantly decreased in the luteal 
phase compared to the follicular phase of the menstrual cycle (P = 0.017, P = 0.002 and 
P < 0.001, respectively). The use of OC seemed to abolish the differences found in 
ADMA and ADMA related parameters in non-OC users between menstrual cycle 
phases and no significant changes were found.
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The use of estrogen containing pills was associated with decreased plasma ADMA  
(P < 0.001), SDMA (P = 0.002) concentrations and ADMA/SDMA ratio (P < 0.001) as 
compared with the non-OC users. On the other hand, L-arginine concentrations            
(P < 0.001) and L-arginine/ADMA ratio (P < 0.001) were higher in the OC-users than in 
the non-OC users. Progestin-only contraceptive pills did not affect plasma ADMA 
concentrations. 
Table 7. The mean concentrations of ADMA, SDMA, L-arginine, ADMA related ratios and hsCRP of 
non-OC users and OC-users in different menstrual cycle phases.
Analyte Early follicular 
phase (μM) 
Late follicular 
phase (μM) 
Early luteal 
phase (μM) 
Late luteal 
phase (μM) 
Non-OC users 
ADMA
(n=159) 
0.642 ± 0.153 
(n=187) 
 0.630 ± 0.136 
(n=116) 
0.605 ± 0.130 
(n=213) 
0.610 ± 0.157 
SDMA 0.382 ± 0.102 0.389 ± 0.106 0.394 ± 0.097 0.382 ± 0.106 
L-arginine 114.8 ± 35.8 115.9 ± 34.5 104.9 ± 30.2 108.7 ± 33.9 
L-Arg/ADMA 180.5 ± 43.4 186.9 ± 53.3 174.3 ± 39.6 181.5 ± 50.9 
ADMA/SDMA 1.72 ± 0.25 1.67 ± 0.30 1.57 ± 0.27 1.63 ± 0.33 
hsCRP 0.65 0.57 0.52 0.70 
OC-users (n=70) (n=80) (n=51) (n=107) 
ADMA 0.551 ± 0.145  0.533 ± 0.131 0.532 ± 0.116 0.542 ± 0.123 
SDMA 0.351 ± 0.094 0.377 ± 0.100 0.383 ± 0.091 0.363 ± 0.077 
L-arginine 126.6 ± 45.7 127.6 ± 40.4 132.6 ± 42.2 130.1 ± 41.2 
L-Arg/ADMA 231.3 ± 65.0 243.7 ± 68.1 252.9 ± 71.8 246.2 ± 77.2 
ADMA/SDMA 1.59 ± 0.23 1.44 ± 0.25 1.42 ± 0.27 1.51 ± 0.23 
hsCRP 1.34 1.50 2.06 2.22 
Results are expressed as mean ± SD. hsCRP is expressed as median. 
ADMA, asymmetric dimethylarginine; hsCRP, high sensitive C-reactive protein; L-Arg, L-arginine; OC, 
oral contraceptives; SDMA, symmetric dimethylarginine. 
48
5.3 Dimethylarginine, L-arginine and L-homoarginine concentrations in non-
pregnant and pregnant states
Concentrations of studied analytes from the original publications have been gathered in 
Table 8. Pregnant women had significantly lower ADMA, SDMA and L-arginine 
concentrations than the corresponding values in non-pregnant women (Figure 4). 
However, there were no significant differences in the concentrations of ADMA and 
SDMA between three trimesters. The L-arginine concentration was lowest in the first 
trimester and then increased up to term, but three months after delivery the 
concentration was still somewhat lower than that detected in non-pregnant women. On 
the contrary, the L-homoarginine concentrations were 2-fold higher in the third 
trimester of pregnancy compared to in non-pregnant women. After delivery, the L-
homoarginine concentration normalized back to the level of non-pregnant women 
within three months. Interestingly, the ADMA and SDMA concentrations appeared to 
be significantly higher after delivery compared to the concentrations during pregnancy. 
Figure 4. Serum asymmetric dimethylarginine (ADMA) (A), symmetric dimethylarginine (SDMA) (B), 
L-arginine (C) and L-homoarginine (D) concentrations in non-pregnant (NP) and pregnant females (P) in 
the The Cardiovascular Risk in Young Finns Study. Results are expressed as mean ± SD. *P < 0.05,    
**P < 0.001 in Mann-Whitney U test. 
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Glomerular filtration rate was clearly elevated in pregnant women compared to non-
pregnant controls and dramatically decreased after delivery to a value even below that 
found in the non-pregnant women (107.7 ± 22.1 vs. 137.1 ± 34.1, P = 0.012). This 
dramatic decrease in GFR after delivery may explain the post-partum increase in both 
ADMA and SDMA levels. Since SDMA is more dependent on urinary excretion than 
ADMA, then the levels of plasma SDMA may increase even more than the 
corresponding values of ADMA. 
Significantly different ADMA/SDMA and L-Arg/ADMA ratios were recorded during 
the non-pregnant and pregnant state as well as after delivery. The lowest 
ADMA/SDMA and L-Arg/ADMA ratios were observed three months after delivery 
(Table 9). 
During pregnancy, ADMA was positively correlated with gestation week (P < 0.01) 
and SDMA (P < 0.001). The association between ADMA and SDMA was also present 
after delivery (P < 0.05). L-homoarginine concentration correlated positively with 
gestational age (P = 0.001) but not with the dimethylarginines or L-arginine. 
Table 8. Summary of mean concentrations of ADMA, SDMA, L-homoarginine and L-arginine in 
different studies.
Study subjects ADMA SDMA    L-homoArg     L-Arg   n  Original 
   (μM)        (μM)     (μM)       (μM)    publication 
Non-pregnant women 
 without OC 0.624 ± 0.149 0.388 ± 0.106      NM  111.1 ± 35.3 761    II 
 with OC 0.541 ± 0.129 0.368 ± 0.092      NM  129.2 ± 41.7 318    II 
Non-pregnant women 0.577 ± 0.071 0.430 ± 0.058    2.7 ± 1.1 100.6 ± 17.1   61    III-V 
Pregnant women 
 1. trimester 0.513 ± 0.082 0.394 ± 0.061    3.1 ± 1.4 87.1 ± 11.5   13    III-V 
 2. trimester 0.518 ± 0.076 0.351 ± 0.033    4.8 ± 1.7 97.2 ± 17.2   22    III-V 
 3. trimester 0.543 ± 0.060 0.434 ± 0.073    5.0 ± 2.2 96.2 ± 19.3   42    III-V 
 after delivery 0.664 ± 0.098 0.568 ± 0.137    2.2 ± 0.8 90.9 ± 16.5     15    IV-V 
Results are expressed as mean ± SD, NM = not measured. 
ADMA, asymmetric dimethylarginine; L-Arg, L-arginine; L-homoArg, L-homoarginine; OC, oral 
contraceptives; SDMA, symmetric dimethylarginine. 
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Table 9. Summary of mean L-arginine/ADMA and ADMA/SDMA ratios in different studies.
Study subjects L-arginine/ ADMA/SDMA n Original  
   ADMA ratio ratio  publication
Non-pregnant women       
 without OC use  181.5 ± 48.2 1.65 ± 0.30 761    II
 with OC use  243.3 ± 71.4 1.49 ± 0.25 318    II 
Non-pregnant women  176.1 ± 33.3 1.36 ± 0.19   61    III-V 
Pregnant women 
 1. trimester  174.7 ± 43.7 1.31 ± 0.15   13    III-V 
 2. trimester  190.2 ± 38.2 1.48 ± 0.20   22    III-V 
 3. trimester  178.6 ± 38.7 1.27 ± 0.16   42    III-V 
 after delivery  138.8 ± 30.8 1.18 ± 0.17   15    IV-V 
Results are expressed as mean ± SD. 
ADMA, asymmetric dimethylarginine; OC, oral contraceptives; SDMA, symmetric dimethylarginine. 
5.4 ADMA and endothelial function 
Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD). 
There were no significant changes in FMD or FMD% during the different phases of the 
menstrual cycle in non-OC users or OC-users. In non-OC users, brachial artery diameter 
remained unchanged during the menstrual cycle, whereas it was significantly decreased 
in the luteal phase (P = 0.013) as compared with the follicular phase in OC-users. In the 
early follicular phase, there was a significant negative correlation between ADMA 
levels and FMD (r = -0.275, P = 0.001) and FMD% (r = -0.280, P < 0.001) and also 
between SDMA levels and FMD (r = -0.186, P = 0.022) and FMD% (r = -0.202,           
P < 0.013) in non-OC users. Whereas in OC-users, there were no correlations between 
ADMA concentrations and FMD during the different menstrual cycle phases. 
When examining all non-pregnant women, both OC and non-OC-users exhibited a 
significant negative correlation between ADMA concentrations and FMD (r = -0.101,   
P = 0.007 and r = -0.139, P = 0.016, respectively) and FMD% (r = -0.088, P = 0.019 and 
r = -0.142, P = 0.013, respectively). Accordingly in non-users, the negative correlation 
of SDMA concentration with FMD or FMD% was significant (P = 0.003 and P = 0.006, 
respectively). 
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The brachial artery diameter was slightly higher during pregnancy compared with 
non-pregnant state (3.17 ± 0.31 vs 3.06 ± 0.32, respectively), although the difference 
was not statistically significant. Also FMD and FMD% tended to increase during 
pregnancy and FMD was statistically different between three trimesters and in non-
pregnant groups (P = 0.008). However, the difference in the FMD% did not reach 
statistical significance between the trimesters and the non-pregnant state groups           
(P = 0.067). The concentrations of ADMA or SDMA did not correlate with FMD 
parameters during pregnancy. L-arginine had a weak negative correlation with FMD in 
non-pregnant women. L-homoarginine correlated positively with FMD and brachial 
artery diameter (P = 0.022 and P = 0.006, respectively) during pregnancy but not in 
non-pregnant women. 
5.5 ADMA and inflammation markers 
The mean serum concentrations of hsCRP and cytokines are presented in Table 10. 
There were significant changes in inflammation markers hsCRP and IL-6 concentrations 
during pregnancy but not in TNF-α concentration. The hsCRP concentration increased 
during the second and the third trimester in comparison with the non-pregnant state     
(P = 0.016 and P = 0.001, respectively). In addition, IL-6 was significantly elevated 
during the third trimester compared with the levels found in non-pregnant women (P = 
0.029). No correlation was found between the concentrations of dimethylarginines or L-
arginine and the measured inflammation markers. 
Table 10. Summary of mean serum hsCRP and cytokine concentrations in study V.
Study subjects hsCRP IL-6 TNF-α n 
   (mg/l)  (pg/ml) (pg/ml)  
Non-pregnant women  3.0 ± 5.3 (1.2) 1.77 ± 1.73 (1.33) 3.42 ± 5.56 (2.38) 61 
Pregnant women 
 1. trimester  3.6 ± 4.1 (2.4) 1.46 ± 0.88 (1.42) 2.19 ± 0.69 (2.20) 13 
 2. trimester  4.4 ± 4.1 (2.9) 1.70 ± 1.36 (1.22) 4.05 ± 7.10 (2.17) 22 
 3. trimester  4.5 ± 4.1 (2.9) 2.05 ± 1.22 (1.75) 2.29 ± 0.86 (2.10) 42 
 after delivery  2.6 ± 2.1 (2.4) 1.47 ± 1.26 (1.28) 1.97 ± 0.70 (1.78) 15 
Results are expressed as mean ± SD (median). 
hsCRP, high sensitive C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.
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The TNF-α/IL-6 ratio is considered to be an index of Th1/Th2 immune response. In 
our study, the median TNF-α/IL-6 ratio decreased during pregnancy and started to 
increase towards the baseline after delivery (Figure 5). The CRP concentration was 2.6-
fold higher in OC-users than in non-OC users but its concentration did not fluctuate 
between menstrual cycle phases. 
Figure 5. Serum tumor necrosis factor-α/interleukin-6 (TNF-α/IL-6) ratio (median) in non-
pregnant females (NP), in three trimesters of normal pregnancy (T1-T3) and post partum period 
(PP). **Significant difference (P = 0.001) was observed in TNF-α/IL-6 ratio between non-
pregnant women and women in the third trimester of pregnancy.
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6 DISCUSSION
6.1 Evaluation of the main results 
The purpose of the present study was devise an ADMA HPLC assay procedure and to 
measure the concentration of endogenous NOS inhibitor ADMA, SDMA, L-
homoarginine and L-arginine in non-pregnant state and in normal pregnancy. We also 
examined whether pregnancy related changes in the maternal body e.g. hyperlipidemia, 
enhanced endothelium-dependent vasodilatation and changes in immune system would 
be associated with concentrations of ADMA and ADMA related compounds. Since the 
non-pregnant control group consisted of women at fertile age, we were interested in 
whether menstrual cycle and the use of oral contraception would have any effect on the 
ADMA concentration such that it would need to be taken into account in the planning of 
future studies. 
In the present study, we observed that the circulating ADMA concentration varied 
across the menstrual cycle in young adult women who were not using hormonal 
contraception. The concentrations of ADMA and L-arginine were significantly lower in 
the luteal phase compared to the follicular phase of the menstrual cycle. In the normal 
menstrual cycle, the estrogen concentration starts to increase towards the end of the 
follicular phase, peaking during the surge of luteinizing hormone and follicle-
stimulating hormone. In addition, the estrogen levels are high during most of the luteal 
phase. The high endogenous estrogen concentration or estrogen and progesterone 
together possibly evoked a decline in the ADMA concentration. High estrogen levels 
may exert an inhibitory action on ADMA accumulation by increasing the production of 
NO by stimulation of the enzyme NOS (Binko and Majewski 1998), upregulation of the 
activity of DDAH and the induction of ADMA degradation (Kimoto et al. 1995), and 
protecting DDAH from oxidative stress which may have an inhibitory effect on its 
enzyme activity (Ito et al. 1999). In women using hormonal contraceptives, there was no 
significant variation in the plasma ADMA concentration across the menstrual cycle but 
the ADMA concentrations were significantly lower in women on estrogen containing 
pills in comparison with those women not using OC. Interestingly, the levels of SDMA, 
the isomer of ADMA, did not exhibit any variations across the menstrual cycle. This 
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may be due to the fact that SDMA is not as sensitive to hormonal changes because it is 
excreted into urine (Kakimoto and Akazawa 1970) and is not eliminated enzymatically 
by DDAH. In the present study, we found that progesterone alone pills did not lower the 
ADMA concentration. Thus one can speculate that the decreasing effect on ADMA was 
associated with fluctuations in the estrogen concentration. 
Hashimoto et al. (1995) evaluated endothelial function by measuring FMD during 
different menstrual cycle phases and they found that FMD was associated with a change 
in the serum estrogen levels. However in previous studies, the variation of FMD during 
the menstrual cycle in women not using OC was not statistically significant in all 
reports but the number of participants in these studies was rather low (Hashimoto et al. 
1995; Kawano et al. 1996, Williams et al. 2001). In accordance with earlier studies, we 
did not find any significant variation in FMD parameters between the different 
menstrual cycle phases in women not using OC. 
The concentrations of ADMA, SDMA and L-arginine were significantly decreased 
during pregnancy as compared with the corresponding levels in non-pregnant controls. 
This is in accordance with some (Fickling et al. 1993; Holden et al. 1998; Maeda et al. 
2003), but not all (Siroen et al. 2006a), previous studies. In the study of Siroen et al. 
(2006a), the decrease in the ADMA level was observed but it was not statistically 
significant because the number of participants in this study was rather low. The 
decreased maternal ADMA concentration may be due to hemodilution and increased 
renal clearance typical of normal pregnancy. In addition, high estrogen levels, which are 
common in normal pregnancy, may inhibit ADMA accumulation. 
Maternal hypercholesterolemia and an elevated triglyceride concentration typically 
occur in normal pregnancies (Saarelainen et al. 2006) and they are believed to be due to 
increased levels of sex steroids and the increased need for adequate supply of nutrients 
to the mother and growing fetus (Chiang et al. 1995). Additionally, reduced total 
peripheral resistance and increases of uterine and placental blood flows during 
pregnancy are fundamental to normal fetal development because an increased blood 
circulation is needed to provide sufficient nutrients and oxygen supplies to the growing 
fetus. The enhanced FMD during pregnancy is thought to be caused by increased NO 
synthesis and general vasodilatation (Cockell and Poston 1997). In a recent study with 
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non-pregnant hypercholesterolemia patients, ADMA was negatively associated with 
FMD (Vladimirova-Kitova et al. 2008). However, we did not find correlation between 
ADMA and FMD regardless of hypercholesterolemic state during normal pregnancy. 
The immune system plays a vital role in pregnancy and cytokines are involved in 
both the maintenance of pregnancy and the onset of normal labor (Elenkov et al. 1999). 
The concentrations of proinflammatory marker, hsCRP, and proinflammatory cytokine, 
IL-6, were increased during the last trimester of pregnancy in comparison with those in 
non-pregnant women. The TNF-α concentration remained unchanged during 
pregnancy. This is in line with earlier studies (Ellis et al. 2001; Sacks et al. 2004; 
Sharma et al. 2007; Aris et al. 2008). Sacks et al. (2004) reported that CRP 
concentration starts to rise as early as gestational week 4 and this suggests that a mild 
systemic inflammation state is present during early pregnancy. Similar to the 
endogenously increased estrogen level encountered during pregnancy, oral 
contraceptives and postmenopausal hormone therapy have been shown to increase the 
concentration of CRP (Kluft et al. 2002; Raitakari et al. 2005; Viikari et al. 2007; 
Haarala et al. 2009). In the present study, we found that there was a positive correlation 
between CRP and IL-6 both in pregnant and non-pregnant women. This finding is in 
accordance with the report that IL-6 can stimulate the production of an acute phase 
protein i.e. CRP, in the liver (Castell et al. 1988). Krzyzanowska et al. (2007b)
suggested that the enhanced inflammation might be associated with elevated plasma 
ADMA levels. However, we did not find any association between the concentrations 
ADMA and CRP, IL-6 or TNF-α. Thus the decreased ADMA concentration may not be 
directly influenced by these proinflammatory markers during normal pregnancy. 
One of the novel findings of the present study was that the concentrations of an 
endogenous amino acid, L-homoarginine, increased during normal pregnancy and there 
was a positive correlation between serum L-homoarginine concentrations and FMD. 
Previous studies have shown that L-homoarginine is a vasodilator (Bhardwaj and Moore 
1989) and can act as a substrate for NOS in a similar manner as L-arginine (Hecker et 
al. 1991; Chen and Sanders 1993; Hrabak et al. 1994). However, it is not possible to 
conclude that L-homoarginine is directly involved in regulating endothelial function in 
normal pregnancy because of the cross-sectional study design. We did not find any 
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correlation between levels of L-homoarginine and ADMA, SDMA or L-arginine. In this 
respect, it is not likely that L-homoarginine is a key regulator of the circulating ADMA 
concentration. Nevertheless, these findings indicate that L-homoarginine has a 
biological function in pregnancy although the significance of this phenomenon is still 
unclear. Since L-homoarginine is widely used as an internal standard in ADMA studies 
by HPLC methods, its use as an internal standard should be avoided if there are 
pregnant subjects included in the study. 
6.2 Validity of the study: Subjects and methodological considerations 
Our study has some limitations. There were subjects from different study populations. 
First, there were subjects from The Cardiovascular Risk in Young Finns Study, which is 
a retrospective non-longitudinal study and has the flaws of a small cross-sectional study. 
The size of this second group was large and rather evenly distributed in the three 
trimesters of pregnant women and in the four menstrual cycle phases of non-pregnant 
women. However, it would have been better if it had been possible to follow the same 
woman through the three trimesters of her pregnancy or over several menstrual cycles 
instead of having only one measurement per pregnant or non-pregnant woman. In 
addition, the measurement of hormonal concentrations in non-pregnant women, 
especially the estrogen concentration, would have provided more information for the 
last study where we evaluated the effect of menstrual cycle on ADMA concentration. 
Another limitation in this study group was that information was unavailable about the 
course of the pregnancy of the study participants and whether were there any 
complications during the late pregnancy. Additionally in cross-sectional studies, 
confounding factors may not be equally distributed between the groups being compared 
and this kind of unequal distribution may bias the results and lead to subsequent 
misinterpretations. Thus causality and temporal sequences cannot be defined. Secondly, 
the subject group from Complicated Pregnancy Study in Kuopio was rather small but it 
did provide the opportunity to study the same mothers once during pregnancy and three 
months after delivery. However, all of the women who attended the first examination 
during their pregnancy were not able to come to the re-examination after delivery. 
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The analysis of ADMA and SDMA is a challenging task because the concentrations 
are in the submicromolar range, whereas the levels of most other amino acids are two to 
three orders of magnitude higher. To date, most published methods for ADMA analysis 
have been HPLC assays and they have been suitable for the simultaneous determination 
of L-arginine, ADMA and SDMA. More recently, methods based on mass spectrometry 
have also been developed but these assays require expensive instrumentation and highly 
skilled personnel, which are not available in every laboratory. However, there has been 
a large variation between ADMA concentrations reported from different measuring 
methods (Table 1) which complicates comparisons between results carried out by 
different research groups. Thus there is a need for commercially available standard 
reference material with traceability against which the calibration of different methods 
could be reliably checked. 
Our ADMA assay had good recovery, excellent linearity, low detection limits and 
good separation efficiency of the analytes. One disadvantage with the present method 
was that the total run time was rather long (38 min), and thus the capacity of the method 
was limited to approximately 24 samples per day. Recently, it has been shown that it is 
possible to decrease the analysis time in the chromatography by using a silica-based 
monolithic C18 column instead of the normal C18 column because its permeable pore 
structure makes it possible to use much higher flow rates (de Jong and Teerlink 2006). 
In addition, this improvement does not decrease the high separation efficiency of the 
peaks, and the backpressure is much lower in comparison with conventional silica 
columns. Other ways to decrease the analysis time are to use smaller particles in the 
column, to decrease the length of the column or to use higher flow rates. ADMA ELISA 
is a commercially available assay which has a larger capacity but it is able to measure 
only one analyte at a time and its precision was worse than that achieved with the HPLC 
method. The intra-assay CV was exceedingly high in the ELISA assay; this may be due 
to the difficulties of pipetting the precipitated sample onto the ELISA plate after 
acylation. Later, Siroká et al. (2006) noted that ADMA ELISA was comparable with 
their HPLC method and its reproducibility was good. However, Horowitz and 
Heresztyn (2006) stated that in their opinion ELISA method was not as selective and 
accurate as HPLC and MS-based methods for ADMA measurements. Since ADMA and 
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SDMA have demonstrated low intra-individual variation (Blackwell et al. 2007) it is 
extremely important that the precision of the assay is good to obtain statistically reliably 
results. 
The assessment of FMD from brachial artery is a non-invasive way of evaluating 
endothelial function. Although the method is not complicated, it does require a highly 
experienced investigator to use the ultrasound equipment and the study subjects should 
be carefully prepared prior to assessment. One limitation of this technique is its low 
long-term reproducibility which might limit the interpretation of the study results. 
However in the Cardiovascular Risk in Young Finns Study (Juonala et al. 2007), the 
between-visit CVs for FMD parameter measurements were in accordance with previous 
studies (Lind et al. 2000; De Roos et al. 2003). 
In cytokine measurements, one limitation is that we used maternal systemic blood 
samples and cytokines are often released locally in tissues and exert their effects on the 
cells adjacent to the release site. However, in vivo samples of placental tissue are 
difficult to obtain from women with normal pregnancies. 
6.3 Clinical significance of the study 
There are only a few large scale studies where the plasma ADMA concentration has 
been measured. Teerlink (2007) has reported a 95% reference interval for ADMA (0.39 
-0.63 μM, HPLC study) in a large population based cohort study (n=2311; age 50-74 
yrs). Schulze et al. (2005) studied 500 subjects with the ELISA method and their 95% 
reference interval was 0.36–1.17 μM. Both studies reported weak but significant 
positive correlations with ADMA levels and age and gender. Thus there is a clear need 
for population reference intervals for different gender and different age groups, in 
addition to women undergoing normal pregnancies, for L-arginine and methylated 
derivatives. An HPLC method was devised for the ADMA measurements which is 
sufficiently accurate and precise for reference interval measurements. In addition, it is 
important to have low inter- and intra-assay variation for measured analytes because 
even very minute increases in the ADMA concentration may be important; for example 
a recent clinical study measured the ADMA pre-operatively and after the surgery (Maas 
et al. 2007). It was demonstrated that each 0.1 μM increase in ADMA was associated 
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with a 33% elevated risk of complications. In the Gothenburg Study of women (n=880), 
it was noted that an 0.15 μM increase in the ADMA concentration was associated with a 
30% increase in risk for fatal and non-fatal myocardial infarction and stroke with the 
relative risk factor being 1.75 in women who had ADMA above 0.71 μM (Leong et al. 
2008). However, it must be noted that a single result from a study subject may be of 
limited diagnostic value. 
In summary, the present studies provide new information about ADMA and related 
compounds regarding pregnancy related phenomenon: endothelial function, immune 
system upregulation and increased lipid concentration during normal pregnancy. In this 
thesis, it was found that the ADMA concentration is dependent on hormonal status of 
the women. Thus if women at fertile age are enrolled in studies, the menstrual cycle 
phase and not only their possible use of hormonal contraception should be taken into 
account. Furthermore, also the type of contraception is important. This applies also to 
CRP measurements where the use of OC seems to increase the circulating CRP 
concentration. On the contrary, endothelial function measured as FMD seemed to be 
unaffected by the menstrual cycle phase. These results may be useful when ADMA 
concentrations from normal pregnancies are compared with the results from 
complicated pregnancies. In the future, there is a clear need for a golden standard with 
tracebility for ADMA measurements so that results from different study groups could be 
comparable with each other. However, at the moment, ADMA measurements are of 
limited importance in clinical use on their own but they may be a useful risk marker and 
predictor of outcome when combined with other biochemical measurements i.e. renal 
clearance, markers of inflammation and endothelial function. 
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7 CONCLUSIONS
The present HPLC assay for ADMA was optimized and it proved to be sensitive and 
selective. The linearity was excellent and the variations within and between assays were 
low. In addition, the detection limits for ADMA and SDMA were low enough to detect 
the small concentrations typically seen in serum and plasma of the normal healthy 
population. The HPLC method is more precise than the current ELISA method and it 
has the advantage of permitting the simultaneous determination of ADMA, SDMA, L-
homoarginine and L-arginine. 
In women not using hormonal contraception, there were significant changes in the 
plasma ADMA and L-arginine concentration during the normal menstrual cycle. The 
use of OC decreased ADMA and SDMA concentrations as compared with non-OC 
users. However, there were no significant changes found in ADMA, SDMA, L-arginine 
concentrations during the various phases of the menstrual cycle in women with OC-use. 
FMD, a marker of endothelial function, was not affected by hormonal cyclic changes of 
menstrual cycle and it can be measured at any phase of the cycle without causing 
erroneous results whereas in ADMA measurements the menstrual cycle phase of the 
woman may interfere with the assay result. 
ADMA, SDMA and L-arginine concentrations were significantly decreased during 
normal pregnancy. Marked hypercholesterolemia and enhanced FMD which is common 
during pregnancy were not associated with serum ADMA levels. 
The L-homoarginine concentration is significantly increased in normal pregnancy in 
comparison with the corresponding value in non-pregnant women or the concentrations 
after delivery. Interestingly, the L-homoarginine concentration was associated with 
FMD but not with serum levels of ADMA or L-arginine in normal pregnancy. L-
homoarginine cannot be used as an internal standard in the ADMA assay if pregnant 
women are included in the study population because it may cause erroneous results. 
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The concentrations of proinflammatory cytokine, IL-6, and inflammation marker, CRP, 
were significantly increased during the third trimester of the normal pregnancy. No 
association was found between levels of dimethylarginines and CRP or IL-6 and TNF-
α. This study indicates that the maternal ADMA and SDMA serum concentrations may 
be decreased due to hemodilution and more extensive renal clearance. It seems that 
ADMA and its related compounds undergo metabolism independent from changes in 
the serum levels of CRP or the studied cytokines in normal pregnancy. 
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